What is Pasireotide?
Pasireotide is a somatostatin analogue studied in Cushing disease. The selected trial measured cortisol control and reported frequent hyperglycemia-related events.
Biological role or research focus
Cushing disease research.
A biochemical response in a subset is not a cure for every patient. The trial compared two regimens rather than treatment with placebo. Novartis funded the study.
Role reference: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
- Class / identity
- Somatostatin analogue
- Research focus
- Cushing disease research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Quick answers
- Is Pasireotide FDA approved?
- Yes. Signifor (NDA 200677, approved 2012) for Cushing's disease. Source ↗
- Is Pasireotide safe?
- Pasireotide is approved for Cushing's disease; blood sugar rises in nearly everyone at first, and the label also warns of low cortisol, slow heart rate, QT prolongation, liver and gallbladder problems. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Pasireotide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Pasireotide Cushing disease phase 3 study (2012) | Human randomized trial | 162 adults with Cushing disease. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2012
Pasireotide Cushing disease phase 3 study
How many participants achieved cortisol control, and what harms occurred?
- Population / model
- 162 adults with Cushing disease.
- Study design
- Double-blind phase 3 comparison of two pasireotide regimens, with an open-label period through 12 months; no placebo arm.
- Main finding
- At month six, urinary cortisol normalized without an increase in the assigned regimen in 12 of 82 and 21 of 80 participants. Hyperglycemia-related adverse events occurred in 118 of 162; 74 started glucose-lowering medication.
- Limits & context
- A biochemical response in a subset is not a cure for every patient. The trial compared two regimens rather than treatment with placebo. Novartis funded the study.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
75 registered studies name Pasireotide as an intervention; 6 are recruiting or under way, 0 have not started recruiting yet, 50 completed and 19 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 75 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Acromegaly. ↗
Nature reviews. Disease primers · 2019 Mar 21 · Journal Article, Review
Pasireotide. ↗
· 2012 · Review
Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome. ↗
Endocrine reviews · 2026 May 13 · Journal Article, Review
Read available full text ↗
Pasireotide. ↗
· 2006 · Review
Risks & interactions
Pasireotide is approved for Cushing's disease; blood sugar rises in nearly everyone at first, and the label also warns of low cortisol, slow heart rate, QT prolongation, liver and gallbladder problems.
Safety is established by FDA labeling. The main trial included about 160 people with Cushing's disease; serious adverse events occurred in about a quarter. The label lists no contraindications, and safety in children is not established.
Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicinesLiver problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Interactions
- Other drugs that prolong the QT interval: added risk of dangerous heart rhythms
- Beta-blockers and calcium channel blockers: may add to a slow heart rate
- Cyclosporine: pasireotide may lower its levels
- Bromocriptine: its levels may rise
Serious risks
- High blood sugar and new or worsening diabetes
- Low cortisol (hypocortisolism)
- Slow heart rate and QT prolongation
- Liver test elevations
- Gallstones and their complications
- Low levels of other pituitary hormones, and poor fat absorption
Common side effects
- diarrhea
- nausea
- high blood sugar
- gallstones
- headache
- abdominal pain
- fatigue
- diabetes
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Signifor (pasireotide) prescribing information ↗
What the featured evidence can tell us
Hyperglycemia is a central concern in this publication. The high event frequency should remain visible alongside cortisol results; current labeling supplies the complete precautions.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Identity, route, and evidence limits
A biochemical response in a subset is not a cure for every patient. The trial compared two regimens rather than treatment with placebo. Novartis funded the study.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Regulatory status
- U.S. FDA approval
- Approved
Signifor (NDA 200677, approved 2012) for Cushing's disease; Signifor LAR (NDA 203255) for acromegaly and Cushing's disease. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
Pasireotide medicines are used for specified Cushing’s disease and acromegaly populations when surgery is unsuitable or unsuccessful. Signifor and Signifor LAR have formulation-dependent indications; results should remain attached to the product actually studied.
The selected report concerns adults with Cushing disease. Current product labels are needed for precise indications, formulations, and monitoring requirements.
Source: MedlinePlus · Pasireotide injection ↗
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
How Pasireotide works
Pasireotide engages somatostatin receptor pathways. In Cushing disease, the treatment strategy aims to alter hormone secretion; biochemical response and clinical outcomes remain separate measurements.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Molecular structure
Questions worth asking
- Does normalized cortisol mean everyone was cured?
- What population, comparator, and route were actually studied?
- A biochemical response in a subset is not a cure for every patient. The trial compared two regimens rather than treatment with placebo. Novartis funded the study.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does normalized cortisol mean everyone was cured?
No. Only a subset met the specified endpoint, and biochemical control is different from resolution of all symptoms or long-term complications.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
